Iovance Biotherapeutics (NASDAQ:IOVA) Shares Rise 7.7% - An Overview

During trading on Thursday, shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) saw a notable increase of 7.7%. The stock reached a high of $7.99 before settling at $7.97 by the end of the trading session. A total of approximately 2,429,683 shares changed hands, reflecting a 66% decrease in volume compared to the average daily volume of 7,189,960 shares. The stock closed the previous day at $7.40.

Recent Analyst Ratings

The performance of Iovance Biotherapeutics has caught the attention of several analysts recently. UBS Group initiated coverage on the company on October 24th, giving it a "buy" rating alongside a price target of $17.00. Subsequently, HC Wainwright reaffirmed a "buy" rating, setting a price target of $32.00 on November 6th. Currently, out of the analysts tracking the stock, one has issued a sell rating, one has given a hold rating, and seven analysts have recommended a buy. This gives the stock a consensus rating of "Moderate Buy" with an average target price of $23.00.

Stock Performance Metrics

Iovance Biotherapeutics holds a market capitalization of about $2.38 billion, with a P/E ratio of -5.25 and a beta value of 0.55. The stock's 50-day moving average stands at $9.02, while its 200-day moving average is $9.26.

Quarterly Earnings Report

The company recently announced its quarterly earnings results on November 7th. Iovance reported earnings of ($0.28) per share for the quarter, which was better than analysts' expectations of ($0.31). The revenue for the quarter amounted to $58.56 million, surpassing the anticipated $53.54 million. Despite these positive indicators, Iovance Biotherapeutics reported a negative net margin of 451.25% and a negative return on equity of 58.43%. Last year during the same quarter, the firm had an EPS of ($0.46). Analysts forecast an EPS of -1.23 for the current fiscal year.

Insider Activity

In insider trading news, Director Ryan D. Maynard sold 50,000 shares of Iovance Biotherapeutics on November 12th. The shares were sold at an average price of $10.06, resulting in a total transaction value of $503,000. Following this transaction, Maynard holds 7,500 shares, currently valued at approximately $75,450, indicating a decrease of about 86.96% in his overall ownership.

Institutional Investments

Several large institutional investors have also made moves recently concerning Iovance Biotherapeutics. For instance, Bank of New York Mellon Corp increased its position in the company by 24.0% during the second quarter, owning 1,034,760 shares worth approximately $8.3 million after acquiring an additional 200,536 shares. Similarly, Principal Financial Group Inc. raised its stake by 26.4%, now holding 2,536,243 shares valued at around $20.3 million. Arizona State Retirement System raised its holdings by 3.8%, now possessing 54,734 shares worth approximately $439,000. Roughly 77.03% of the company’s stock is currently owned by institutional investors.

Company Overview

Iovance Biotherapeutics, Inc. specializes in the development and commercialization of cell therapies, particularly using autologous tumor infiltrating lymphocytes for treating metastatic melanoma and other solid tumor cancers in the U.S. The primary offerings include Amtagvi, a tumor-derived autologous T cell immunotherapy for adult patients with unresectable or metastatic melanoma, and Proleukin, an interleukin-2 product designed for treating patients with metastatic renal cell carcinoma.

Investment Considerations

Before deciding on investing in Iovance Biotherapeutics, it is crucial to consider various factors dependent on market conditions and analysts' recommendations. The consensus rating suggests a "Moderate Buy," but it is advised to research and analyze potential alternative investment opportunities that might prove to be more favorable further into the market.

Iovance, stocks, analysis